What is KORU Medical Systems, Inc.'s earnings per share (EPS)?

KORU Medical Systems, Inc. (KRMD) reported diluted earnings per share of -$0.06 for fiscal year 2025. This represents a 53.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

KORU Medical Systems, Inc. (KRMD) Financials

KRMD

Trailing 12 months to June 30, 2026

Revenue $45.1M +22.4% YoY

Net Income -$1.8M +59.7% YoY

EPS (Diluted) -$0.10 -233.3% YoY

Free Cash Flow $777K +134.0% YoY

Market Cap $136.7M as of Oct 10, 2026

Price / Sales 3.0x on $45.1M revenue, trailing 12 months to June 30, 2026

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to June 30, 2026

Price / Book 7.6x on $18.1M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 5, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the KRMD SEC filings page.

KORU Medical Systems, Inc. (KRMD) reported $45.1M in revenue over the twelve months to Jun 30, 2026, up 22.4% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI KRMD FY2025 2026-10-03

Revenue growth is finally reaching operating results, but cash conversion remains incomplete and profitability is not yet established.

Over the last two reported years, revenue rose to $41.1M while gross margin held above 62.0%. With operating losses narrowing while gross margin stayed broadly stable, the recent improvement points more to fixed-cost absorption than to a richer product mix.

In the latest year, operating cash flow turned positive at $462K while free cash flow was -$470K. That split means operations nearly funded themselves, but reinvestment still kept total cash generation below zero.

Latest total liabilities were $11.2M against $17.0M of equity, so the balance sheet is not debt-dominated despite the accumulated losses. The current ratio was 2.4x, down from 7.8x in FY2021, showing the liquidity cushion has narrowed as liabilities rose while assets contracted.

Financial Health Signals

Financial Health Score 66/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of KORU Medical Systems, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

KORU Medical Systems, Inc. held $8.9M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations generated $462K of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and KORU Medical Systems, Inc. scores 86/100 among other emerging companies.

Dilution

KORU Medical Systems, Inc. had 46M shares outstanding at the end of fiscal year 2025, against 46M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and KORU Medical Systems, Inc. scores 70/100 among other emerging companies.

R&D Intensity

KORU Medical Systems, Inc. spent $4.4M on research and development in fiscal year 2025, which was 9.9% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and KORU Medical Systems, Inc. scores 36/100 among other emerging companies.

Revenue Progress

KORU Medical Systems, Inc. reported revenue of $41.1M in fiscal year 2025, against $33.6M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and KORU Medical Systems, Inc. scores 65/100 among other emerging companies.

Burn Trend

KORU Medical Systems, Inc.'s operations generated $462K of cash in fiscal year 2025, against $320K used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and KORU Medical Systems, Inc. scores 88/100 among other emerging companies.

Balance Sheet

KORU Medical Systems, Inc.'s cash, cash equivalents and investments came to $8.9M at the end of fiscal year 2025, against $11.2M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and KORU Medical Systems, Inc. scores 53/100 among other emerging companies.

Altman Z-Score Safe

7.38

KORU Medical Systems, Inc. scores 7.38, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($136.7M) relative to total liabilities ($11.2M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

4/8

KORU Medical Systems, Inc. passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.

Earnings Quality Mixed

N/A

KORU Medical Systems, Inc. reported a net loss of $2.6M while generating $462K in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$12.0M

YoY+18.2%

QoQ+2.4%

5Y CAGR+16.9%

KORU Medical Systems, Inc. generated $12.0M in revenue in Q2 2026. This represents an increase of 18.2% from the same quarter a year earlier. Against the prior quarter it is up 2.4%.

EBITDA

$837K

YoY+911.3%

QoQ+225.4%

KORU Medical Systems, Inc.'s EBITDA was $837K in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 911.3% from the same quarter a year earlier. Against the prior quarter it is up 225.4%.

Net Income

$252K

YoY+222.0%

QoQ+131.3%

KORU Medical Systems, Inc. reported $252K in net income in Q2 2026. This represents an increase of 222.0% from the same quarter a year earlier. Against the prior quarter it is up 131.3%.

EPS (Diluted)

$0.01

KORU Medical Systems, Inc. earned $0.01 per diluted share (EPS) in Q2 2026.

Cash & Balance Sheet

Free Cash Flow

$108K

YoY+122.1%

QoQ+443.5%

KORU Medical Systems, Inc. generated $108K in free cash flow in Q2 2026, representing cash available after capex. This represents an increase of 122.1% from the same quarter a year earlier. Against the prior quarter it is up 443.5%.

Cash & Debt

$8.3M

YoY+2.9%

QoQ-5.5%

5Y CAGR-20.8%

10Y CAGR+8.8%

KORU Medical Systems, Inc. held $8.3M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

46M

YoY-0.1%

5Y CAGR+0.7%

10Y CAGR+2.0%

KORU Medical Systems, Inc. had 46M shares outstanding in Q2 2026. This represents a decrease of 0.1% from the same quarter a year earlier.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

65.1%

YoY+1.6pp

QoQ+3.7pp

5Y change+7.1pp

KORU Medical Systems, Inc.'s gross margin was 65.1% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 1.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 3.7 percentage points.

Operating Margin

5.2%

YoY+8.3pp

QoQ+12.6pp

5Y change+30.2pp

KORU Medical Systems, Inc.'s operating margin was 5.2% in Q2 2026, reflecting core business profitability. This is up 8.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 12.6 percentage points.

Net Margin

2.1%

YoY+4.1pp

QoQ+9.0pp

5Y change+22.4pp

KORU Medical Systems, Inc.'s net profit margin was 2.1% in Q2 2026, showing the share of revenue converted to profit. This is up 4.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 9.0 percentage points.

Return on Equity

1.4%

YoY+2.7pp

QoQ+6.2pp

5Y change+4.4pp

KORU Medical Systems, Inc.'s ROE was 1.4% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 2.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 6.2 percentage points.

Capital Allocation

R&D Spending

$1.1M

YoY-10.5%

QoQ-18.8%

5Y CAGR+22.5%

KORU Medical Systems, Inc. invested $1.1M in research and development in Q2 2026. This represents a decrease of 10.5% from the same quarter a year earlier. Against the prior quarter it is down 18.8%.

Capital Expenditures

$108K

YoY+274.5%

QoQ+133.8%

5Y CAGR+13.7%

10Y CAGR+3.8%

KORU Medical Systems, Inc. invested $108K in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 274.5% from the same quarter a year earlier. Against the prior quarter it is up 133.8%.

Share Buybacks

Not reported for Q2 2026.

KRMD Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

KRMD quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$45.1M	$41.1M+22.2%	$33.6M+18.0%	$28.5M+2.2%	$27.9M+18.8%	$23.5M-2.8%	$24.2M+4.4%	$23.2M+33.5%	$17.4M+41.2%	$12.3M+0.4%	$12.2M+8.9%	$11.2M+29.3%	$8.7M+12.0%	$7.8M+21.5%	$6.4M+29.9%	$4.9M
Cost of Revenue	$16.9M	$15.5M+26.1%	$12.3M+4.3%	$11.8M-5.7%	$12.5M+28.9%	$9.7M+5.2%	$9.2M+11.2%	$8.3M+27.0%	$6.5M+38.5%	$4.7M+1.7%	$4.6M+1.9%	$4.6M+34.5%	$3.4M+20.2%	$2.8M+25.2%	$2.3M+35.9%	$1.7M
Gross Profit	$28.2M	$25.6M+20.0%	$21.3M+27.7%	$16.7M+8.7%	$15.4M+11.6%	$13.8M-7.8%	$14.9M+0.6%	$14.9M+37.4%	$10.8M+42.8%	$7.6M-0.4%	$7.6M+13.7%	$6.7M+25.9%	$5.3M+7.4%	$4.9M+19.5%	$4.1M+26.8%	$3.3M
R&D Expenses	$4.5M	$4.4M-16.6%	$5.3M-8.4%	$5.7M+15.9%	$5.0M+100.4%	$2.5M+90.8%	$1.3M+75.1%	$740K+207.1%	$241K+1.5%	$237K+14.6%	$207K-55.7%	$468K+114.6%	$218K+47.8%	$148K+63.4%	$90K+154.3%	$36K
SG&A Expenses	$24.6M	$23.4M+8.1%	$21.6M+6.2%	$20.4M-1.2%	$20.6M+15.4%	$17.9M+48.5%	$12.0M+23.1%	$9.8M+19.2%	$8.2M+5.5%	$7.8M+30.7%	$5.9M+24.1%	$4.8M+24.3%	$3.9M+8.7%	$3.5M+33.4%	$2.7M+35.0%	$2.0M
Operating Income	-$1.7M	-$3.0M+53.9%	-$6.4M+37.2%	-$10.3M+4.7%	-$10.8M-53.4%	-$7.0M-460.2%	-$1.3M-314.2%	$586K-49.7%	$1.2M+258.2%	-$736K-162.3%	$1.2M+3.0%	$1.1M+13.9%	$1.0M-5.2%	$1.1M-17.6%	$1.3M+7.9%	$1.2M
EBITDA	N/A	-$2.2M+61.1%	-$5.6M+40.9%	-$9.4M+7.8%	-$10.2M-55.2%	-$6.6M-685.3%	-$836K-190.3%	$926K-37.2%	$1.5M+438.3%	-$436K-130.0%	$1.5M+1.5%	$1.4M+15.4%	$1.2M-1.0%	$1.3M-10.0%	$1.4M+10.5%	$1.3M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$2K-44.7%	$3K+566.4%	$512-88.7%	$5K-83.9%	$28K-10.3%	$32K-13.3%	$36K
Income Tax	N/A	$22K+656.7%	$3K-99.9%	$4.0M+297.0%	-$2.0M-11.8%	-$1.8M-10021.4%	-$18K-113.5%	$132K-50.4%	$266K+210.2%	-$242K-167.2%	$360K+11.9%	$321K+4.7%	$307K-1.7%	$312K-32.9%	$465K-4.9%	$489K
Net Income	-$1.8M	-$2.6M+56.5%	-$6.1M+55.9%	-$13.7M-58.7%	-$8.7M-89.8%	-$4.6M-276.5%	-$1.2M-314.8%	$564K-38.0%	$911K+270.2%	-$535K-168.3%	$783K+3.9%	$753K+7.1%	$703K-3.1%	$726K-11.0%	$816K+15.9%	$704K
EPS (Basic)	N/A	-$0.06+53.8%	-$0.13+56.7%	-$0.30-57.9%	-$0.19-90.0%	-$0.10-233.3%	-$0.03-400.0%	$0.01-50.0%	$0.02+300.0%	-$0.01-150.0%	$0.020.0%	$0.020.0%	$0.020.0%	$0.020.0%	$0.020.0%	$0.02
EPS (Diluted)	-$0.10	-$0.06+53.8%	-$0.13+56.7%	-$0.30-57.9%	-$0.19-90.0%	-$0.10-233.3%	-$0.03-400.0%	$0.01-50.0%	$0.02+300.0%	-$0.01-150.0%	$0.020.0%	$0.020.0%	$0.020.0%	$0.020.0%	$0.020.0%	$0.02
Diluted Shares (Avg)	N/A	46M+0.8%	46M+0.4%	46M+1.3%	45M+1.4%	44M+5.9%	42M+7.3%	39M+0.4%	39M+2.8%	38M-0.3%	38M+0.9%	38M+2.7%	37M+1.7%	36M+2.7%	35M-4.7%	37M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$12.0M+18.2%	$11.8M+22.1%	$10.9M+23.3%	$10.4M+27.2%	$10.2M+20.9%	$9.6M+17.5%	$8.8M+23.0%	$8.2M+16.8%
Cost of Revenue	$4.2M+12.9%	$4.5M+26.3%	$4.1M+24.5%	$4.1M+38.2%	$3.7M+26.1%	$3.6M+16.0%	$3.3M+14.7%	$3.0M+12.5%
Gross Profit	$7.8M+21.2%	$7.2M+19.6%	$6.8M+22.6%	$6.3M+20.8%	$6.5M+18.2%	$6.0M+18.5%	$5.6M+28.4%	$5.2M+19.4%
R&D Expenses	$1.1M-10.5%	$1.3M+18.1%	$1.1M+2.7%	$933K-39.2%	$1.2M+5.3%	$1.1M-24.5%	$1.1M-13.5%	$1.5M+18.6%
SG&A Expenses	$5.9M+10.3%	$6.6M+10.5%	$6.0M+3.7%	$6.0M+16.9%	$5.4M+1.2%	$6.0M+11.2%	$5.8M+16.2%	$5.1M+10.9%
Operating Income	$627K+300.5%	-$865K+30.5%	-$547K+65.6%	-$868K+49.1%	-$313K+73.8%	-$1.2M+36.5%	-$1.6M+27.7%	-$1.7M+4.9%
EBITDA	$837K+911.3%	-$667K+35.1%	-$368K+73.3%	-$663K+55.1%	-$103K+89.4%	-$1.0M+40.6%	-$1.4M+30.0%	-$1.5M+6.3%
Income Tax	$6K-66.6%	N/A	N/A	-$150	$17K	N/A	N/A	N/A
Net Income	$252K+222.0%	-$807K+30.8%	-$487K+68.8%	-$778K+50.8%	-$207K+79.1%	-$1.2M+39.8%	-$1.6M+79.1%	-$1.6M-15.5%
EPS (Basic)	$0.01	-$0.02+33.3%	N/A	N/A	$0.00+100.0%	-$0.03-175.0%	-$0.03+81.3%	-$0.030.0%
EPS (Diluted)	$0.01	-$0.02+33.3%	-$0.11	$0.02-33.3%	$0.00-100.0%	-$0.03-175.0%	-$0.03+81.3%	$0.03+200.0%
Diluted Shares (Avg)	50M+7.2%	46M+0.8%	N/A	46M+0.8%	46M+0.8%	46M+0.6%	N/A	46M+0.5%

Not reported in any period shown, so not listed: Interest Expense.

KRMD Balance Sheet

KRMD quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$28.2M+3.6%	$27.2M-4.4%	$28.5M-32.8%	$42.3M+2.5%	$41.3M+3.4%	$39.9M+187.6%	$13.9M+31.6%	$10.5M+29.1%	$8.2M-2.7%	$8.4M+15.3%	$7.3M+17.3%	$6.2M+11.0%	$5.6M+16.4%	$4.8M+39.9%	$3.4M
Current Assets	$20.0M+4.5%	$19.1M-5.5%	$20.3M-32.0%	$29.8M-20.1%	$37.3M-0.5%	$37.5M+215.8%	$11.9M+31.5%	$9.0M+33.2%	$6.8M-4.8%	$7.1M+20.5%	$5.9M+11.6%	$5.3M+14.3%	$4.6M+8.9%	$4.3M+41.1%	$3.0M
Cash & Equivalents	$8.9M-7.4%	$9.6M-16.6%	$11.5M-34.0%	$17.4M-31.3%	$25.3M-7.3%	$27.3M+365.3%	$5.9M+57.0%	$3.7M+8.2%	$3.5M-17.8%	$4.2M+64.3%	$2.6M+14.8%	$2.2M+15.4%	$1.9M+9.9%	$1.8M+32.9%	$1.3M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$3.7M+31.2%	$2.8M-19.5%	$3.5M-45.6%	$6.4M+4.9%	$6.1M-10.6%	$6.8M+185.9%	$2.4M+13.5%	$2.1M+55.4%	$1.4M+30.1%	$1.0M-15.2%	$1.2M+49.8%	$819K-28.8%	$1.2M-1.5%	$1.2M+74.7%	$668K
Accounts Receivable	$6.2M+8.6%	$5.7M+41.4%	$4.0M+13.7%	$3.6M-0.9%	$3.6M+39.6%	$2.6M-20.5%	$3.2M+126.8%	$1.4M-5.1%	$1.5M+11.2%	$1.4M-16.8%	$1.6M-6.9%	$1.7M+56.5%	$1.1M+26.0%	$885K+23.9%	$714K
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$11.2M+7.2%	$10.4M+28.3%	$8.1M-26.3%	$11.0M+129.7%	$4.8M+27.4%	$3.8M+42.2%	$2.6M+67.0%	$1.6M+6.0%	$1.5M+17.1%	$1.3M+26.6%	$1.0M-0.9%	$1.0M-17.7%	$1.2M-1.5%	$1.3M+31.5%	$954K
Current Liabilities	$8.2M+13.8%	$7.2M+61.7%	$4.5M-36.0%	$7.0M+45.2%	$4.8M+30.7%	$3.7M+52.4%	$2.4M+51.9%	$1.6M+14.0%	$1.4M+25.4%	$1.1M+60.2%	$692K-10.4%	$772K+46.9%	$525K-6.0%	$559K+77.9%	$314K
Non-Current Liabilities	$3.0M-7.7%	$3.2M-12.3%	$3.7M-9.7%	$4.0M	$0-100.0%	$96K-60.1%	$239K	$0-100.0%	$105K-37.6%	$168K-46.8%	$316K+29.0%	$245K-65.5%	$710K+2.1%	$696K+8.7%	$640K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$394K-10.3%	$439K	N/A
Total Equity	$17.0M+1.4%	$16.8M-17.4%	$20.4M-35.0%	$31.3M-14.2%	$36.5M+1.0%	$36.2M+221.8%	$11.2M+25.4%	$9.0M+34.2%	$6.7M-6.2%	$7.1M+13.5%	$6.3M+20.8%	$5.2M+19.2%	$4.4M+22.7%	$3.6M+43.1%	$2.5M
Retained Earnings	-$32.0M-9.0%	-$29.4M-26.0%	-$23.3M-143.6%	-$9.6M-951.7%	-$910K-124.9%	$3.7M-24.9%	$4.9M+13.1%	$4.3M+73.1%	$2.5M-17.7%	$3.0M+35.0%	$2.2M+50.8%	$1.5M+90.1%	$781K+1325.2%	$55K+107.2%	-$761K

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$28.0M+9.6%	$28.6M+5.1%	$28.2M+3.6%	$27.1M-1.0%	$25.5M-6.5%	$27.2M-1.0%	$27.2M-4.4%	$27.4M-22.5%
Current Assets	$19.5M+11.0%	$20.6M+8.4%	$20.0M+4.5%	$19.4M+2.6%	$17.6M-9.2%	$19.0M-2.5%	$19.1M-5.5%	$18.9M-12.7%
Cash & Equivalents	$8.3M+2.9%	$8.8M+0.4%	$8.9M-7.4%	$8.5M-3.9%	$8.1M-23.0%	$8.7M-19.3%	$9.6M-16.6%	$8.8M-18.2%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$4.5M+14.3%	$4.5M+36.5%	$3.7M+31.2%	$4.4M+12.3%	$3.9M+52.5%	$3.3M+4.2%	$2.8M-19.5%	$3.9M-16.0%
Accounts Receivable	N/A	$6.0M+0.6%	$6.2M+8.6%	$5.4M+4.8%	$4.9M-15.7%	$5.9M+35.4%	$5.7M+41.4%	$5.2M+27.5%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$9.9M+10.2%	$11.7M+7.3%	$11.2M+7.2%	$10.6M+10.2%	$9.0M+4.5%	$10.9M+29.7%	$10.4M+28.3%	$9.7M+21.9%
Current Liabilities	$7.2M+18.7%	$8.9M+13.5%	$8.2M+13.8%	$7.8M+23.9%	$6.1M+17.8%	$7.8M+60.7%	$7.2M+61.7%	$6.3M+49.8%
Non-Current Liabilities	$2.7M-7.1%	$2.8M-8.3%	$3.0M-7.7%	$2.8M-15.8%	$2.9M-15.1%	$3.1M-13.0%	$3.2M-12.3%	$3.3M-10.0%
Total Equity	$18.1M+9.2%	$16.9M+3.5%	$17.0M+1.4%	$16.5M-7.2%	$16.5M-11.6%	$16.3M-14.5%	$16.8M-17.4%	$17.7M-35.4%
Retained Earnings	-$32.6M-5.9%	-$32.8M-7.5%	-$32.0M-9.0%	-$31.5M-13.3%	-$30.8M-17.2%	-$30.5M-21.0%	-$29.4M-26.0%	-$27.8M-75.5%

Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.

KRMD Cash Flow Statement

KRMD quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$1.4M	$462K+244.6%	-$320K+93.5%	-$4.9M+9.5%	-$5.4M-25.1%	-$4.3M-481.1%	-$743K-331.8%	$321K-78.3%	$1.5M+546.2%	-$332K-117.3%	$1.9M+131.8%	$826K-13.4%	$954K+21.6%	$785K+40.0%	$561K-45.5%	$1.0M
Depreciation & Amortization	N/A	$811K-8.8%	$888K+2.1%	$870K+48.2%	$587K+26.8%	$463K+10.6%	$419K+23.0%	$340K+10.0%	$309K+2.9%	$301K+10.7%	$272K-4.3%	$284K+21.9%	$233K+22.0%	$191K+83.7%	$104K+58.1%	$66K
Stock-Based Compensation	N/A	$2.7M+3.4%	$2.6M-5.2%	$2.8M-10.1%	$3.1M+13.7%	$2.7M+67.3%	$1.6M+34.4%	$1.2M+229.1%	$366K+78.2%	$205K+79.4%	$115K+43.6%	$80K-39.5%	$132K+64.6%	$80K	N/A	$13K
Capital Expenditures	$614K	$933K-28.1%	$1.3M+65.7%	$783K-71.6%	$2.8M+697.6%	$346K-62.4%	$921K+357.6%	$201K-32.3%	$297K+46.2%	$203K+66.8%	$122K-79.4%	$591K+213.4%	$189K-66.5%	$564K+138.6%	$236K+17.8%	$201K
Free Cash Flow	$777K	-$470K+70.9%	-$1.6M+71.5%	-$5.7M+30.5%	-$8.2M-75.0%	-$4.7M-180.4%	-$1.7M-1493.0%	$119K-89.9%	$1.2M+321.2%	-$535K-129.8%	$1.8M+664.0%	$235K-69.4%	$766K+246.1%	$221K-31.8%	$324K-60.8%	$828K
Investing Cash Flow	-$1.1M	-$950K+28.8%	-$1.3M-63.6%	-$815K+70.9%	-$2.8M-665.1%	-$366K+64.7%	-$1.0M-179.1%	$1.3M+175.7%	-$1.7M-315.5%	-$416K	N/A	-$745K-241.7%	-$218K+61.6%	-$568K-67.6%	-$339K+4.0%	-$353K
Financing Cash Flow	-$17K	-$221K+10.9%	-$249K-13.6%	-$219K-178.3%	$279K-89.7%	$2.7M-88.4%	$23.2M+4532.7%	$501K+3374.2%	$14K	N/A	N/A	$249K+156.6%	-$439K-910.0%	-$43K-120.4%	$213K+228.4%	-$166K
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$3K	N/A	N/A	N/A	$24K	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	$216K+146.9%	$15K+106.2%	$1.1M+16.5%	$65K+107.1%	-$460K-4161.2%	-$237K+31.5%	$940K-14.3%	-$924K+21.4%
Depreciation & Amortization	$210K+0.3%	$198K-9.1%	$179K-15.3%	$204K-10.2%	$209K-3.8%	$217K-6.1%	$211K-7.4%	$228K+5.4%
Stock-Based Compensation	N/A	$682K-2.3%	N/A	N/A	N/A	$698K-0.3%	N/A	N/A
Capital Expenditures	$108K+274.5%	$46K-89.6%	$408K+836.0%	$52K-95.2%	$29K-76.8%	$443K+233.2%	-$44K-77.8%	$1.1M+412.0%
Free Cash Flow	$108K+122.1%	-$32K+95.4%	$687K-23.3%	$13K+100.6%	-$489K-333.1%	-$681K-41.9%	$896K-0.5%	-$2.0M-44.8%
Investing Cash Flow	-$577K-1903.8%	-$90K+79.9%	-$422K-931.0%	-$52K+95.2%	-$29K+80.6%	-$447K-235.8%	$51K+124.3%	-$1.1M-415.9%
Financing Cash Flow	-$119K+38.1%	-$29K+81.8%	-$265K-22.8%	$396K+5.8%	-$192K+14.7%	-$161K+11.7%	-$216K-20.9%	$374K-15.1%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

KRMD Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

KRMD quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	62.3%-1.1pp	63.4%+4.8pp	58.6%+3.5pp	55.1%-3.5pp	58.6%-3.2pp	61.8%-2.3pp	64.1%+1.8pp	62.3%+0.7pp	61.6%-0.5pp	62.1%+2.6pp	59.5%-1.6pp	61.0%-2.6pp	63.7%-1.1pp	64.8%-1.5pp	66.3%
Operating Margin	-7.2%+11.9pp	-19.2%+16.8pp	-36.0%+2.6pp	-38.6%-8.7pp	-29.9%-24.7pp	-5.2%-7.7pp	2.5%-4.2pp	6.7%+12.7pp	-6.0%-15.6pp	9.7%-0.5pp	10.2%-1.4pp	11.6%-2.1pp	13.7%-6.5pp	20.2%-4.1pp	24.3%
Net Margin	-6.4%+11.6pp	-18.0%+30.1pp	-48.2%-17.1pp	-31.1%-11.6pp	-19.4%-14.4pp	-5.0%-7.4pp	2.4%-2.8pp	5.3%+9.6pp	-4.3%-10.7pp	6.4%-0.3pp	6.7%-1.4pp	8.1%-1.3pp	9.3%-3.4pp	12.8%-1.5pp	14.3%
Return on Equity	-15.5%+20.6pp	-36.1%+31.4pp	-67.5%-39.9pp	-27.7%-15.2pp	-12.5%-9.2pp	-3.4%-8.4pp	5.0%-5.1pp	10.2%+18.2pp	-8.0%-19.0pp	11.0%-1.0pp	12.0%-1.6pp	13.6%-3.1pp	16.7%-6.3pp	23.0%-5.4pp	28.4%
Return on Assets	-9.3%+12.9pp	-22.3%+26.0pp	-48.3%-27.8pp	-20.5%-9.4pp	-11.1%-8.0pp	-3.0%-7.1pp	4.1%-4.6pp	8.6%+15.2pp	-6.6%-15.9pp	9.3%-1.0pp	10.3%-1.0pp	11.3%-1.7pp	13.0%-4.0pp	17.0%-3.5pp	20.5%
Current Ratio	2.44-0.2x	2.66-1.9x	4.55+0.3x	4.28-3.5x	7.79-2.4x	10.23+5.3x	4.94-0.8x	5.70+0.8x	4.88-1.5x	6.43-2.1x	8.54+1.7x	6.86-2.0x	8.82+1.2x	7.61-2.0x	9.60
Debt-to-Equity	0.650.0x	0.62+0.2x	0.400.0x	0.35+0.2x	0.130.0x	0.10-0.1x	0.24+0.1x	0.180.0x	0.220.0x	0.180.0x	0.160.0x	0.20+0.1x	0.090.0x	0.12-0.3x	0.38
Asset Turnover	1.46+0.2x	1.24+0.2x	1.00+0.3x	0.66+0.1x	0.570.0x	0.61-1.1x	1.670.0x	1.65+0.1x	1.500.0x	1.46-0.1x	1.54+0.1x	1.400.0x	1.39+0.1x	1.33-0.1x	1.43
FCF Margin	-1.1%+3.7pp	-4.8%+15.1pp	-19.9%+9.4pp	-29.3%-9.4pp	-19.9%-13.0pp	-6.9%-7.4pp	0.5%-6.3pp	6.8%+11.2pp	-4.3%-19.0pp	14.6%+12.6pp	2.1%-6.7pp	8.8%+5.9pp	2.9%-2.2pp	5.1%-11.8pp	16.8%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	65.1%+1.6pp	61.5%-1.3pp	62.6%-0.4pp	60.2%-3.2pp	63.5%-1.5pp	62.7%+0.5pp	62.9%+2.7pp	63.4%+1.4pp
Operating Margin	5.2%+8.3pp	-7.3%+5.6pp	-5.0%+13.0pp	-8.3%+12.5pp	-3.1%+11.1pp	-12.9%+11.0pp	-18.0%+12.6pp	-20.8%+4.7pp
Net Margin	2.1%+4.1pp	-6.9%+5.2pp	-4.5%+13.2pp	-7.5%+11.8pp	-2.0%+9.7pp	-12.1%+11.5pp	-17.7%	-19.3%+0.2pp
Return on Equity	1.4%+2.7pp	-4.8%+2.4pp	-2.9%+6.4pp	-4.7%+4.2pp	-1.3%+4.0pp	-7.1%+3.0pp	-9.3%+27.4pp	-8.9%-3.9pp
Return on Assets	0.9%+1.7pp	-2.8%+1.5pp	-1.7%+4.0pp	-2.9%+2.9pp	-0.8%+2.8pp	-4.3%+2.8pp	-5.7%+20.5pp	-5.8%-1.9pp
Current Ratio	2.72-0.2x	2.33-0.1x	2.44-0.2x	2.48-0.5x	2.91-0.9x	2.44-1.6x	2.66-1.9x	2.99-2.1x
Debt-to-Equity	0.550.0x	0.690.0x	0.650.0x	0.65+0.1x	0.54+0.1x	0.67+0.2x	0.62+0.2x	0.54+0.3x
Asset Turnover	0.430.0x	0.41+0.1x	0.39+0.1x	0.38+0.1x	0.40+0.1x	0.35+0.1x	0.32+0.1x	0.30+0.1x
FCF Margin	0.9%+5.7pp	-0.3%+6.8pp	6.3%-3.8pp	0.1%+24.7pp	-4.8%-3.5pp	-7.1%-1.2pp	10.1%-2.4pp	-24.5%-4.7pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
KORU Medical Systems, Inc. KRMD	FY2025	$41.1M	-$2.6M	-6.4%	$136.7M	66/100
Utah Medical Products Inc UTMD	FY2025	$38.5M	$11.3M	29.3%	$236.6M	78/100
Anteris Technologies Global Corp. AVR	FY2025	$1.9M	-$94.1M	N/A	$659.8M	22/100
InfuSystem Holdings, Inc. INFU	FY2025	$143.4M	$6.6M	4.6%	$270.1M	59/100
Microbot Medical, Inc. MBOT	FY2025	N/A	-$13.1M	N/A	$71.9M	—

Where KORU Medical Systems, Inc. Ranks

Frequently Asked Questions

What is KORU Medical Systems, Inc.'s annual revenue?

KORU Medical Systems, Inc. (KRMD) reported $41.1M in total revenue for fiscal year 2025. This represents a 22.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is KORU Medical Systems, Inc.'s revenue growing?

KORU Medical Systems, Inc. (KRMD) revenue grew by 22.2% year-over-year, from $33.6M to $41.1M in fiscal year 2025.

Is KORU Medical Systems, Inc. profitable?

No, KORU Medical Systems, Inc. (KRMD) reported a net income of -$2.6M in fiscal year 2025, with a net profit margin of -6.4%.

What is KORU Medical Systems, Inc.'s EBITDA?

KORU Medical Systems, Inc. (KRMD) had EBITDA of -$2.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is KORU Medical Systems, Inc.'s gross margin?

KORU Medical Systems, Inc. (KRMD) had a gross margin of 62.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is KORU Medical Systems, Inc.'s operating margin?

KORU Medical Systems, Inc. (KRMD) had an operating margin of -7.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is KORU Medical Systems, Inc.'s net profit margin?

KORU Medical Systems, Inc. (KRMD) had a net profit margin of -6.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is KORU Medical Systems, Inc.'s return on equity (ROE)?

KORU Medical Systems, Inc. (KRMD) has a return on equity of -15.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is KORU Medical Systems, Inc.'s free cash flow?

KORU Medical Systems, Inc. (KRMD) recorded an outflow of $470K in free cash flow during fiscal year 2025. This represents a 70.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is KORU Medical Systems, Inc.'s operating cash flow?

KORU Medical Systems, Inc. (KRMD) generated $462K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are KORU Medical Systems, Inc.'s total assets?

KORU Medical Systems, Inc. (KRMD) had $28.2M in total assets as of fiscal year 2025, including both current and long-term assets.

What are KORU Medical Systems, Inc.'s capital expenditures?

KORU Medical Systems, Inc. (KRMD) invested $933K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does KORU Medical Systems, Inc. spend on research and development?

KORU Medical Systems, Inc. (KRMD) invested $4.4M in research and development during fiscal year 2025.

How many shares does KORU Medical Systems, Inc. have outstanding?

KORU Medical Systems, Inc. (KRMD) had 46M shares outstanding as of fiscal year 2025.

What is KORU Medical Systems, Inc.'s current ratio?

KORU Medical Systems, Inc. (KRMD) had a current ratio of 2.44 as of fiscal year 2025, which is generally considered healthy.

What is KORU Medical Systems, Inc.'s debt-to-equity ratio?

KORU Medical Systems, Inc. (KRMD) had a debt-to-equity ratio of 0.65 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is KORU Medical Systems, Inc.'s return on assets (ROA)?

KORU Medical Systems, Inc. (KRMD) had a return on assets of -9.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is KORU Medical Systems, Inc.'s P/E ratio?

KORU Medical Systems, Inc. (KRMD) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $136.7M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is KORU Medical Systems, Inc.'s price-to-sales ratio?

KORU Medical Systems, Inc. (KRMD) trades at 3.0x sales, its market capitalization divided by revenue of $45.1M revenue, trailing 12 months to June 30, 2026. The market capitalization is $136.7M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is KORU Medical Systems, Inc.'s Altman Z-Score?

KORU Medical Systems, Inc. (KRMD) has an Altman Z-Score of 7.38, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is KORU Medical Systems, Inc.'s Piotroski F-Score?

KORU Medical Systems, Inc. (KRMD) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are KORU Medical Systems, Inc.'s earnings high quality?

KORU Medical Systems, Inc. (KRMD) reported a net loss of $2.6M while generating $462K in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is KORU Medical Systems, Inc.?

KORU Medical Systems, Inc. (KRMD) scores 66 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.